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Despite substantial risk reductions targeting low-density lipoprotein cholesterol with statins, there remains signif-
icant residual risk as evidenced by incident and recurrent cardiovascular disease (CVD) events among statin-
treated patients. Observational studies have shown that low levels of high-density lipoprotein cholesterol (HDL-C)
are associated with increased CVD risk. It remains unclear whether strategies aimed at increasing HDL-C in addi-
tion to background statin therapy will further reduce risk. The AIM-HIGH (Atherothrombosis Intervention in Meta-
bolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial, which compared
combined niacin/simvastatin with simvastatin alone, failed to demonstrate an incremental benefit of niacin
among patients with atherosclerotic CVD and on-treatment low-density lipoprotein cholesterol values 70 mg/dl,
but this study had some limitations. Previously, small randomized, clinical trials of niacin plus statins showed
that modest regression of carotid atherosclerosis is possible in individuals with CVD, CVD risk equivalents, or
atherosclerosis. This viewpoint summarizes these imaging trials studying niacin and places them in the context
of the failure of AIM-HIGH to support the HDL-C–increasing hypothesis. (J Am Coll Cardiol 2012;59:2058–64)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.0453-Hydroxy-3-methylglutaryl-coenzyme A reductase inhib-
itors (statins) are the standard of care for the management of
dyslipidemia. Although statins provide 25% to 40% reduc-
tions in cardiovascular disease (CVD) risk, there is consid-
erable residual risk in persons who receive this therapy. Two
mechanistically distinct adjunctive treatment options in-
clude efforts to further reduce low-density lipoprotein cho-
lesterol (LDL-C) or attempts to increase high-density
lipoprotein cholesterol (HDL-C). Triglyceride lowering
(and, thus, further apolipoprotein B lowering) is also im-
portant, and non–HDL-C is a secondary target goal in the
Adult Treatment Panel III guidelines.
No agent solely increases HDL-C. Fibric acid derivatives
(peroxisome proliferator-activated receptor X agonists) up-
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2012, accepted January 25, 2012.regulate 60 genes and decrease triglyceride levels. Cho-
lesteryl ester transfer protein (CETP) inhibitors markedly
increase HDL-C, but certain CETP inhibitors also lower
LDL-C by 25% to 40% and lower triglycerides. The full
mechanism of action of niacin is still unclear (1,2). Niacin
increases HDL-C by approximately 20% and also lowers
LDL-C, triglycerides, and lipoprotein(a).
In a few previous studies, niacin therapy led to clinically
significant relative risk reductions in clinical events and
either stabilization or modest regression of atherosclerosis
(3–5). However, the HATS [HDL Atherosclerosis Treat-
ment Study] (3) (simvastatin-niacin vs. placebo with or
without antioxidants) and FATS [Familial Atherosclerosis
Treatment Study] (4) (lovastatin-colestipol vs. niacin-
colestipol vs. conventional therapy) trials did not have a
statin-only group. The number of clinical endpoints in
HATS and FATS was modest, although there was a
reduction in the CVD primary endpoint in HATS with
simvastatin-niacin versus placebo when antioxidants were
not used. HATS also showed a reduction in the progression
of coronary stenosis with the niacin-simvastatin combina-
tion compared with placebo (Table 1).
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June 5, 2012:2058–64 Niacin Surrogate Trials and the AIM-HIGH TrialThe Coronary Drug Project was a pre-statin era second-
ary prevention trial that randomized 1,119 subjects to
clofibrate or niacin. Nine years after termination of the
Coronary Drug Project, niacin still conferred an 11%
reduction in all-cause mortality compared with placebo (p 
0.0004) (5). A recent meta-analysis supported the benefit of
niacin alone or in combination with other lipid-lowering
drugs in reducing CVD events and atherosclerosis, although
most of the studies in this meta-analysis were conducted
before statin therapy (6). Thus, whether a strategy to
increase HDL-C using adjunct pharmacotherapy to a back-
round of statin treatment confers additional risk reduction
emains unknown.
Several small randomized controlled trials (RCTs) (ARBITER
Arterial Biology for the Investigation of the Treatment Effects of
educing Cholesterol] [7,8], HALTS [9], Oxford Niaspan
10], and NIA [National Institute on Aging] Plaque [11])
tested the effect of adding niacin to statin therapy on the
surrogate endpoint of carotid atherosclerosis among indi-
viduals with coronary heart disease (CHD) or risk equiva-
lents (Table 1). These trials studied a relatively modest
number of patients over a relatively short treatment period.
Therefore, RCTs powered for clinical endpoints are re-
quired to determine whether combined niacin/statin ther-
apy is more effective than statin monotherapy alone. The
AIM-HIGH (Atherothrombosis Intervention in Metabolic
Syndrome With Low HDL/High Triglycerides: Impact on
Global Health Outcomes) trial (12) reported disappointing
results, whereas the larger HPS2-THRIVE (Treatment of
HDL to Reduce the Incidence of Vascular Events) trial is
still under way. This viewpoint summarizes some of the
surrogate imaging trials using niacin-statin combination
therapy and places them in the context of the AIM-HIGH
findings.
Review of the Niacin RCTs
With Surrogate Endpoints
The ARBITER-2 and -3. ARBITER-2 tested 1,000 mg
xtended-release niacin (ERN) versus placebo on top of
ackground statin therapy on the change in mean common
arotid intima-media thickness (cIMT) measured by
-mode ultrasound (7). Niacin-treated patients without
nsulin resistance experienced reduced cIMT progression
ompared with those treated with placebo. Extended out to
4 months in ARBITER-3, combined niacin/statin therapy
onferred cIMT regression (8). Clinical endpoints were few
n ARBITER-2 and not significantly different between
roups.
he HALTS trial. The HALTS trial (9) compared the
ffects of 2 adjunctive lipid-lowering medications, ezetimibe
nd ERN, added to background statin therapy. At 14
onths, assignment to niacin conferred a significant average
eduction of cIMT, whereas the cIMT measurements in the
zetimibe group were unchanged. The incidence of CVD
vents was lower in the niacin group (2 [1%] vs. 9 [5%], p0.029), although the study was
not powered for clinical end-
points (9). In an exploratory
analysis, increasing niacin expo-
sure resulted in a further reduc-
tion in cIMT, whereas increased
cumulative ezetimibe exposure
was associated with cIMT pro-
gression (13).
The implications of the HALTS
trial were provocative, but raised
a few concerns. First, 10%
withdrew because of side effects,
with a differential dropout in the
niacin and ezetimibe groups (27
vs. 9). Individuals less able to
handle the side effects of niacin
might also be less compliant with
other secondary prevention mea-
sures. Removing these potentially less compliant subjects
could be a source of bias; however, the authors did show that
the baseline characteristics and 2-month lipid changes were
similar between “completers” and “withdrawers.”
Unfortunately, the HALTS trial results do not allow us
to conclude that all HDL-C–increasing therapies are supe-
rior to LDL-C–lowering therapies. For example, despite
substantial increases in HDL-C levels conferred by treat-
ment with the CETP inhibitor torcetrapib, this did not
translate to any benefit (rather increased harm) in the
ILLUMINATE (Investigation of Lipid Level Management
to Understand its Impact in Atherosclerotic Events) trial,
although blood pressure increases related to increased aldoste-
rone may have negated the favorable changes in lipids (14).
The Oxford Niaspan study. The Oxford Niaspan study
(10) was a smaller (N 71) RCT of modified-release niacin
(target 2,000 mg/day) versus placebo added to baseline
statin therapy on the primary endpoint of change in com-
mon carotid artery wall area by magnetic resonance imaging
at 1 year. Like the HALTS trial, there was a differential
dropout related to side effects. Only 22 niacin-treated and
29 placebo-treated participants completed the study (63%
vs. 81% study completion, respectively). After 12 months,
there was carotid wall area regression in the niacin group
compared with progression in the placebo group. Thus, the
regression of carotid plaque seen with niacin was concordant
with the findings of the HALTS trial.
The NIA Plaque study. On the other hand, the results of
the NIA (National Institute on Aging) Plaque study (11)
did not suggest a benefit of the addition of niacin to
statin therapy among well-treated older participants with
high vascular risk but higher mean HDL-C levels.
Regression of carotid plaque was seen with aggressive
standard medical therapy including statins, but a similar
degree of regression occurred in both the niacin and
placebo arms. Final conclusions regarding this study must
Abbreviations
and Acronyms
CETP  cholesteryl ester
transfer protein
CHD  coronary heart
disease
cIMT  carotid intima-
media thickness
CVD  cardiovascular
disease
ERN  extended-release
niacin
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
RCT  randomized
controlled trialbe ultimately deferred until the full article is published.
Niacin  Statin Imaging RCTsTable 1 Niacin  Statin Imaging RCTs
Trial, Year
Published (Ref. #) Drug Therapy Participants
Mean Baseline
Lipids, mg/dl
Length of Follow-Up,
Months
Lipid Changes
During Trial Surrogate Endpoint Clinical Events
HATS, 2001 (3) Simvastatin-niacin (doses
titrated) vs. placebo;
with or without
antioxidants
N  160; known CHD,
low HDL (35 mg/dl),
and LDL (145 mg/dl)
LDL 130,
HDL 32
36 LDL decreased 42% and
HDL increased 26%
with simvastatin-niacin
compared with
placebo. Results
attenuated with
antioxidants
On coronary angiography; the average
coronary stenosis progressed by
3.9% with placebo, 1.8% with
antioxidants (p  0.16), and 0.7%
with simvastatin-niacin plus
antioxidants (p  0.004) and
regressed by 0.4% with
simvastatin-niacin alone
(p  0.001)
9 events in the placebo arm
vs. 1 event in the niacin-
simvastatin arm (without
antioxidants), 90%
reduction (p  0.03);
however, events (n  6)
in the niacin-simvastatin
with antioxidants group
not significantly reduced
ARBITER-2,
2004 (7)
ERN (1,000 mg/day) vs.
placebo
Background statin therapy
N  167; known CHD;
low HDL (45 mg/dl)
LDL 89 20,
HDL 40 7
12 HDL increased 21% in
niacin group
Overall, no difference in cIMT
progression between niacin and
placebo (p  0.08); among
subjects without insulin resistance,
niacin reduced cIMT progression
(p  0.026)
No difference in clinical CVD
events; events occurred
in 3 niacin (3.8%) and
7 placebo (9.6%)
patients; p  0.20
ARBITER-3,
2006 (8)
ERN 1,000 mg/day N  130;
ARBITER-2 participants who
either continued on or crossed
over (from placebo) to ERN
12–24 HDL increased 8 mg/dl on
average
Among 57 participants treated with
ERN for 24 months, there was
regression of cIMT of
0.041 0.021 mm
(p  0.001 vs. placebo)
N/A
HALTS, 2009 (9) ERN (target 2,000 mg/day)
vs. ezetimib
Background statin therapy
N  363; documented
CVD or risk equivalents.
LDL 100 mg/dl and
low HDL-C (50 [men]/
55 [women] mg/dl)
LDL 82 23,
HDL 42 9
14 (study stopped
early after 208
completed trial)
Both niacin and ezetimibe
reduced LDL (10 vs.
18 mg/dl lower on
average, respectively)
(p  0.01). HDL was
increased in niacin
(8 mg/dl on average),
whereas HDL
decreased in ezetimibe
(3 mg/dl) groups
(p  0.001)
Niacin conferred average reduction of
0.014 0.004 mm in the
common cIMT (p  0.001) and
0.018 0.005 mm in maximum
cIMT (p  0.001), whereas cIMT
in the ezetimibe group was
unchanged (p  0.8)
Fewer CVD events in the
niacin group compared
with ezetimibe (2 [1%]
vs. 9 [5%], p  0.04)
Oxford, 2009 (10) Modified-release niacin
(target 2,000 mg/day)
vs. placebo; background
statin therapy
N  71; CHD or risk equivalent;
low HDL (40 mg/dl)
LDL 85,
HDL 38
12 Niacin increased HDL by
23% and lowered LDL
by 19%
Compared with placebo, niacin
significantly reduced carotid wall
area on MRI (1.64 mm2,
p  0.03)
N/A
NIA, 2009 (11) ERN (1,500 mg/day) vs.
placebo; background
statin therapy
N  145; age 65 yrs with
high vascular risk;
LDL-C 125 mg/dl;
no HDL-C cutoff for entry
LDL 87,
HDL 55
18 Compared with placebo,
ERN resulted in
significantly lower LDL
(67 vs. 77 mg/dl,
p  0.03) and higher
HDL (58 vs. 49 mg/dl,
p  0.001)
Using carotid wall volume measured
by MRI, regression of carotid
plaque was seen with aggressive
standard medical therapy including
statins, but a similar degree of
regression occurred in both the
niacin and placebo arms
N/A
CHD coronary heart disease; cIMT carotid intima-media thickness; CVD cardiovascular disease; ERN extended-release niacin; HDL high-density lipoprotein; LDL low-density lipoprotein; MRImagnetic resonance imaging; N/A not available; RCT randomized,
clinical trial.
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June 5, 2012:2058–64 Niacin Surrogate Trials and the AIM-HIGH TrialReconciling Differences
Between the Surrogate Studies
Although the HALTS trial (9) and the Oxford Niaspan
Study (10) suggested niacin conferred more regression of
carotid disease (cIMT or wall area) compared with
ezetimibe or placebo, preliminary data from NIA Plaque
study (11) showed that in an older, generally well-treated
group, the addition of niacin failed to offer incremental
benefit over statin therapy. Differences between the study
results may be due: 1) the site imaged; 2) differences in the
primary outcome; 3) differences in baseline HDL-C values;
or 4) differences in LDL-C achieved on therapy.
Use of Surrogate Endpoint to
Predict Atherosclerotic CVD Events
Whether demonstration of a treatment effect of niacin on
imaging measures translates to actual clinical benefit re-
mains unknown. Controversy also exists about which
marker of subclinical atherosclerosis is the best marker for
predicting future CVD risk.
B-mode ultrasound imaging is a sensitive and reproduc-
ible method for the assessment of cIMT in the hands of an
experienced technologist and investigator. In observational
studies, cIMT predicts future CHD and stroke (15). How-
ever, surrogate markers of atherosclerosis from various
vascular beds (coronary artery calcium, cIMT, ankle-
brachial index) are only modestly correlated with each other,
and coronary artery calcium is more strongly predictive of
CHD events than cIMT (16). cIMT is only somewhat
correlated with coronary atherosclerosis and may not fully
mirror CHD events.
Other limitations to the use of surrogate markers include
potential differential response to statins. For example, statin
therapy does not slow the progression of another surrogate
marker, coronary artery calcium. Foam cell accumulation in
the carotid arteries, the principal pathological feature of an
increased cIMT, is likely the main component that is
capable of regression; direct comparisons of cIMT and
magnetic resonance imaging–measured regression in the
context of statins are not available.
In addition, it remains unclear whether a reduction in
cIMT progression or actual regression obtained with a
pharmacological treatment is necessarily followed by a
decrease in coronary atherosclerosis and events. Hormone
therapy and thiazolidinediones retard the progression of
cIMT (17,18) but may be associated with adverse CVD
events (19). Although cIMT has been deemed an acceptable
surrogate endpoint for statin trials (20), a meta-analysis of
41 trials enrolling 18,307 participants suggested that regres-
sion or slowed progression of cIMT induced by cardiovas-
cular drugs does not always reflect a decrease in cardiovas-
cular events (21).
The final word on the additive power of niacin on top of
aggressive statin therapy will only come from RCTs pow- mered for clinical event endpoints, and the use of surrogate
markers as reliable indicators of future CVD events should
be viewed with healthy skepticism.
Review of the Niacin RCTs
With Clinical Endpoints
The AIM-HIGH trial. The AIM-HIGH trial (12) was a
double-blind RCT that enrolled patients with a history of
CVD and atherogenic dyslipidemia (lipid entry criteria
varied by sex and statin dose at screening). All participants
received simvastatin ( ezetimibe) at a dose sufficient to
maintain an LDL-C level of 40 to 80 mg/dl. There was an
open-label niacin run-in phase to determine tolerance of at
least 1,500 mg/day of niacin, and 20% of those enrolled
dropped out because of niacin intolerance. Niacin-tolerant
participants (N 3,414) were then randomized to ERN (at
1,500 to 2,000 mg/day) or placebo (which contained a
50-mg dose of immediate-release niacin to help ensure
blinding).
The mean age was 64 9 years, 85% were men, and 92%
ere white. Metabolic risk factors and vascular disease were
ighly prevalent (34% diabetes, 71% hypertension, 81%
etabolic syndrome, and 92% coronary disease). Statin
herapy was used by 94% of enrolled patients before enroll-
ent. Before randomization, the mean LDL-C was 71
g/dl, HDL-C was 34 mg/dl, and the triglyceride level was
61 mg/dl among statin-treated participants.
AIM-HIGH ended earlier than expected after a mean
ollow-up of 3 years after an interim analysis was conducted
uggesting futility in proving its hypothesis. The on-
reatment achieved mean LDL-C was 65  22 mg/dl and
8  19 mg/dl, and HDL-C values were 44  11 and 39  8
g/dl in the niacin/simvastatin and placebo/simvastatin
rms, respectively. Of the participants, 25% and 20% in the
iacin and placebo arms, respectively, discontinued the
tudy drug (p  0.001).
Analyses were conducted by intention-to-treat methods.
uring the 36-month follow-up period, the primary out-
ome occurred with 274 events in the placebo/simvastatin
rm (16%) and 282 events in the niacin/simvastatin arm
16%) (hazard ratio: 1.02; 95% confidence interval: 0.87 to
.21; p  0.79). There was no significant subgroup inter-
ction found including for those with a previous myocardial
nfarction or statin use at entry. A subgroup analysis of
utcomes by baseline lipid status (such as LDL-C 70
g/dl vs. 70 mg/dl) was not presented in the main paper.
The results of AIM-HIGH are disappointing. Perhaps in
hese predominantly statin-treated patients generally at lipid
oals, coronary plaque might have already been depleted of
ts lipid core. The results of AIM-HIGH should not
ecessarily be extrapolated to other patient populations such
s those with LDL-C 100 mg/dl for whom there still
ight be a role for niacin. With just 3,414 participants,
IM-HIGH was relatively small for a clinical trial in the
odern era of background medical therapy. Designed for a
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Niacin Surrogate Trials and the AIM-HIGH Trial June 5, 2012:2058–64power to detect a 25% reduction in the primary outcome,
anticipating 800 events was perhaps optimistic. With only
556 events, the study may have been underpowered to see a
difference between the groups.
AIM-HIGH does not lend itself to a direct compari-
son of niacin versus placebo because the study design
allowed titration of statin dosing and the addition of
ezetimibe to keep LDL-C within a range of 40 to 80
mg/dl. Because niacin has LDL-C–lowering effects, this
meant greater use of higher simvastatin doses in the
placebo arm (25% of the placebo arm was taking simva-
statin 80 mg vs. 18% of the niacin arm, p  0.02) and
lso more ezetimibe in the placebo arm (22% vs. 10%,
 0.001), which likely also confounded the results.
Finally, AIM-HIGH also does not necessarily negate the
DL-raising hypothesis. The difference in on-treatment
edian HDL-C between niacin and placebo was only
odest (4 mg/dl); thus, results of AIM-HIGH cannot be
xtrapolated to other HDL-C–increasing therapies such as
ETP inhibitors.
There is an ongoing substudy of AIM-HIGH with the
rimary outcome of change in mean plaque lipid composi-
ion assessed by carotid magnetic resonance imaging, which
ay shed light on the apparent discordance between surro-
ate endpoints using imaging and clinical events.
he HPS2-THRIVE trial. Despite AIM-HIGH, the
verdict is not yet in for niacin because there is still a much
larger niacin RCT in progress. HPS2-THRIVE (Treat-
ment of HDL to Reduce the Incidence of Vascular Events)
(niacin/laropiprant vs. placebo on a background of simva-
statin  ezetimibe, N  25,000), is anticipated to be
completed in 2013.
Other non-niacin large RCTs recently completed or in
progress. Both fibrates and omega-3 fatty acids have
modest HDL-C–increasing properties and have also been
studied as adjunctive agents to statin therapy. Although
ACCORD (Action to Control Cardiovascular Risk in
Diabetes) failed to show an incremental benefit of combined
fenofibrate/simvastatin versus simvastatin alone among di-
abetics in the overall trial, subgroup analyses did suggest a
benefit for those with marked dyslipidemia (triglycerides
204 mg/dl and HDL 34 mg/dl) (22). In the JELIS
(Japan EPA Lipid Intervention Study) study, there was an
incremental benefit of adding eicosapentaenoic acid supple-
ments to background statin therapy with a decrease in CVD
events by 19% among patients with a history of CHD (23).
In contrast, the OMEGA (Effect of Omega 3-Fatty Acids
on the Reduction of Sudden Cardiac Death After Myocar-
dial Infarction) study failed to show any additional CVD
benefit at 1 year of omega-3 fatty acids when combined with
modern guideline-adjusted therapy after myocardial infarc-
tion (24).
Two CETP inhibitor drugs are also currently in phase III
RCTs (2). Dal-OUTCOMES (N  15,600) randomized
patients with acute coronary syndromes to dalcetrapib or
placebo and is anticipated to be completed in 2013.REVEAL (Randomized EValuation of the Effects of Anac-
etrapib Through Lipid-modification) HPS3–TIMI 55
(N  30,000) is a trial of participants with established
CHD, vascular disease, or diabetes randomized to anac-
etrapib or placebo on a background of atorvastatin use, with
study completion anticipated in 2017.
IMPROVE-IT (IMProved Reduction of Outcomes:
Vytorin Efficacy International Trial) vs Simvastatin) (N 
18,000) (25) is evaluating the role of further LDL-C
reduction and modest HDL-C increases with ezetimibe/
simvastatin versus simvastatin alone in patients with acute coro-
nary syndromes.
Concluding Thoughts
HDL-targeted therapeutics in a post-ILLUMINATE,
post-AIM-HIGH era. ILLUMINATE (14) and AIM-
HIGH (12) demonstrated that increasing HDL-C levels
through pharmacotherapy is neither adequate nor necessary
for predicting cardiovascular benefit. Low HDL-C levels
may be simply a marker of risk, given its association with
metabolic syndrome and insulin resistance, and not a causal
factor. If this is the case, a strategy to increase HDL-C
levels via pharmacotherapy may not translate to additional
clinical benefit.
There are other therapeutic agents under investigation
targeting HDL-C (2). Other oral medications include the
CETP inhibitors, niacin receptor (GPR109A) agonists,
liver X receptor agonists, peroxisome proliferator–activated
receptor agonists, and oral apolipoprotein A-I mimetic
peptides. Parenteral approaches include apolipoprotein A-I
(Milano or wild type) phospholipid complexes, apolipopro-
tein A-I mimetic peptides, or delipidated autologous HDL.
Improving HDL-C function will be the focus of new
therapies (2), particularly through enhancing reverse cho-
lesterol transport but perhaps also through HDL-C’s pro-
posed antithrombotic, antioxidant, and anti-inflammatory
properties. These studies mandate improved standardized
methods to assess HDL-C function.
Reaching the target LDL: statin monotherapy versus
combination therapy. LDL-C remains the primary target
of lipid therapy with non–HDL-C as the secondary target.
It remains unknown whether more aggressive LDL-C
reduction with a more potent statin would be more effective
than adding a second lipid-modifying agent to a less potent
statin or lower statin dose. For most high-risk patients,
reduction of 50% of LDL-C is needed to achieve an
LDL-C 70 mg/dl and a non–HDL-C 100 mg/dl. All
of the subjects with established vascular disease or high risk
of CVD in the surrogate endpoint RCTs and AIM-HIGH
would have an optional LDL-C goal of 70 mg/dl, but the
mean LDL-C in these trials was 70 mg/dl at enrollment.
The baseline mean LDL-C in AIM-HIGH was lower
than in the HALTS and Oxford studies, which may
partially explain the lack of benefit for additional niacin
therapy.
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June 5, 2012:2058–64 Niacin Surrogate Trials and the AIM-HIGH TrialThe SANDS (Stop Atherosclerosis in Native Diabetics
Study) compared the effects of aggressive LDL-C–lowering
strategy (target LDL-C goal 70 mg/dl) with those of a
standard-treated group (LDL-C goal 100 mg/dl) (26).
Among the aggressively treated group (with approximately
one third taking the statin/ezetimibe combination), a sim-
ilar regression of cIMT at 3 years was seen in subjects who
attained equivalent LDL-C reductions from statin alone or
a statin plus ezetimibe. The standard-treated group showed
an increase in cIMT.
For adults with increased metabolic risk, intensified
lifestyle changes remain an important target of therapy;
weight loss can have substantial impact on triglyceride levels
and inflammatory markers. In secondary prevention pa-
tients, the evidence supports initially increasing doses of a
statin to reach LDL-C goals. If a patient cannot reach his
or her lipid goals (i.e., LDL-C and non–HDL-C) with a
potent statin alone, the choices remain a fibrate, niacin,
bile acid sequestrant, phytosterols, or ezetimibe as add-on
therapy. Unfortunately, the published studies to date do
not provide a definitive answer as to which of these
therapies should be chosen when LDL-C and non–
HDL-C goals cannot be reached despite maximally
tolerated statin therapy.
Summary
Although low HDL-C remains a marker of residual risk
even among statin-treated individuals treated to reach
aggressive lipid goals (27), after AIM-HIGH, there likely
will be less enthusiasm for starting niacin therapy in patients
with low HDL-C who have well-controlled LDL-C (70
mg/dl). This does not necessarily mean that niacin lacks a
role in lipid-modifying therapy. Pending different conclu-
sions from the upcoming HPS2-THRIVE, there may
remain a place for niacin in high-risk patients who cannot
reach the LDL-C goal of 70 mg/dl despite maximally
tolerated statin therapy or in statin-intolerant patients. At
this time, there is no clear indication to withdraw niacin in
patients receiving this therapy if further LDL-C reduction
is needed.
Clinicians should await larger ongoing clinical trials such
as HPS2-THRIVE, Dal-OUTCOMES, REVEAL, and
IMPROVE-IT to determine whether there is benefit of the
addition of lipid-modifying agents to background statin
therapy. The role of niacin or other lipid-modifying agents
among patients optimally treated with statin therapy re-
mains uncertain, and time will tell whether HDL-C–
targeted therapeutics will live up to their hype.
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